2020 -- H 7840 | |
======== | |
LC004806 | |
======== | |
STATE OF RHODE ISLAND | |
IN GENERAL ASSEMBLY | |
JANUARY SESSION, A.D. 2020 | |
____________ | |
A N A C T | |
RELATING TO INSURANCE -- ACCIDENT AND SICKNESS INSURANCE POLICIES | |
| |
Introduced By: Representative Julie A. Casimiro | |
Date Introduced: February 26, 2020 | |
Referred To: House Health, Education & Welfare | |
It is enacted by the General Assembly as follows: | |
1 | SECTION 1. Purpose and legislative findings. |
2 | (a) Purpose. It is the policy of the state of Rhode Island not to permit introduction of |
3 | pollutants into the ground waters and water systems of the state or otherwise to be discharged in |
4 | concentrations which are known to be toxic, carcinogenic, mutagenic, or teratogenic as the same |
5 | are defined in the Rhode Island department of environmental management groundwater quality |
6 | rules and the rules and regulations for hazardous waste management. More specifically, the Rhode |
7 | Island department of environmental management, in regulation #DEM OWM-HW 01-14, most |
8 | recent revision dated January 7, 2014, defines certain antineoplastic or cytotoxic chemotherapy |
9 | agents and drugs as "Extremely Hazardous Waste." |
10 | (b) Findings. |
11 | (1) The Drug Quality and Security Act (H.R. 3204) is a new federal law that amended the |
12 | Federal Food, Drug, and Cosmetic Act to grant the Food and Drug Administration more authority |
13 | to regulate and monitor the manufacturing and handling of compounded drugs. This bill was written |
14 | in response to the New England Compounding Center meningitis outbreak that took place in 2012, |
15 | which killed sixty-four (64) people. The bill was signed into law by President Obama on November |
16 | 27, 2013. |
17 | (2) This act mandated that the FDA order the United States Pharmacopeia (USP) to set |
18 | standards for compounding drugs. USP 800 was published in 2017 and took effect December 1, |
19 | 2019. These standards require the control of certain cytotoxic chemotherapy drugs from the time |
| |
1 | they arrive at the pharmacy, all the way through excretion of the drugs by the patient. |
2 | (3) This mandate puts an enormous financial burden on the Rhode Island hospital system, |
3 | insurance companies, Medicaid and the people of Rhode Island. This cost should be carried by the |
4 | producers of therapies that are used in combination with cytotoxic drugs as well as the producers |
5 | of cytotoxic drugs |
6 | (4) This federal mandate requires that the waste follow all federal, state, and local |
7 | regulations including #DEM OWM-HW 01-14 which defines "Extremely Hazardous Waste." |
8 | (5) It is acknowledged by medical experts that bodily wastes of patients undergoing |
9 | chemotherapy treatment may contain levels of chemicals that are toxic, carcinogenic, mutagenic or |
10 | teratogenic for a certain period of time, to such an extent that the World Health Organization defines |
11 | genotoxic waste as chemotherapy drug waste including urine, feces and vomit from patients, which |
12 | may contain potentially hazardous amounts of the administered cytostatic drugs or of their |
13 | metabolites, and which should be considered genotoxic for at least forty-eight (48) hours and |
14 | sometimes up to one week after drug administration. According to the World Health Organization, |
15 | ten percent (10 %) of known carcinogens are chemicals used to cure cancer. |
16 | (6) While, according to the American Society of Clinical Oncology, the cost of one |
17 | additional cancer patient resulting from the exposure to these harmful chemicals is approximately |
18 | one hundred seventy thousand dollars ($170,000) per treatment year, the cost of the implementation |
19 | of cytotoxic chemical safety protocols is estimated to be less than two percent (2%) of that cost. |
20 | (7) The World Health Organization further states that any discharge of genotoxic waste |
21 | into the environment could have disastrous ecological consequences. The World Health |
22 | Organization places the responsibility for genotoxic waste on the chief pharmacist and further states |
23 | that the chief pharmacist also has the special responsibility of ensuring that genotoxic products are |
24 | used safely, and that genotoxic waste is managed safely. |
25 | (8) The European Commission, Executive Agency for Health and Consumers undertook a |
26 | comprehensive "Study on the environmental risks of medicinal products" which was released in |
27 | June of 2014, drafted by BIO Intelligence Service, a division of Deloitte Consulting LLP, reviewing |
28 | the prevalence of contaminants in drinking water and noting the extreme dangers arising from |
29 | improper disposal of cytotoxic chemotherapy drugs. |
30 | (9) Dr. Christian G. Daughton, former chief of environmental chemistry for the United |
31 | States Environmental Protection Agency, notes in a paper entitled "Eco-directed sustainable |
32 | prescribing: feasibility for reducing water contamination by drugs" published in the journal |
33 | "Science of the Total Environment" on June 3, 2014, that generally, the best practice for lowering |
34 | the level of drugs in our environment is reduction of dosages, but that "[c]ertain drug classes |
| LC004806 - Page 2 of 19 |
1 | (especially cytotoxic chemotherapeutics) may not be amenable to this approach; the best control |
2 | measure for such highly toxic drugs may simply be the prevention of urine and feces from entering |
3 | sewers." |
4 | (10) The federal Occupational Safety and Health Administration ("OSHA") is the main |
5 | federal agency charged with the enforcement of safety and health legislation. OSHA, in concert |
6 | with the National Institute for Occupational Safety and Health ("NIOSH") and the Joint |
7 | Commission on Healthcare, an independent, not-for-profit organization that accredits and certifies |
8 | more than twenty thousand (20,000) health care organizations and programs in the United States, |
9 | stated in a 2011 letter to every hospital in the country that "[e]very day in healthcare settings across |
10 | America, workers are exposed to hundreds of powerful drugs used for cancer chemotherapy, |
11 | antiviral treatments, hormone regimens and other therapies. While these drugs are used to relieve |
12 | and heal patients, many of them present serious hazards to the health and safety of your workers. |
13 | Some of these drugs have been known to cause cancer, reproductive and developmental problems, |
14 | allergic reactions, and other adverse effects that can be irreversible even after low-level exposures." |
15 | (11) Further, because of the risk of ongoing exposure to these extremely hazardous |
16 | excreted drugs, the American Cancer Society has published a comprehensive list of safety |
17 | precautions regarding the in-home personal hygiene for individuals undergoing chemotherapy and |
18 | their families. |
19 | (12) Therefore, for the protection of both the public health and the environment, the general |
20 | assembly shall require that standards are set forth pursuant to these sections to address this serious |
21 | health and safety issue. |
22 | SECTION 2. Chapter 27-18 of the General Laws entitled "Individual Health Insurance |
23 | Coverage" is hereby amended by adding thereto the following section: |
24 | 27-18-85. Cancer patient safety and environmental protection. |
25 | (a) Chemotherapy precautions following treatment. All physicians, pharmacists, or other |
26 | health care professionals licensed in the state of Rhode Island authorized to prescribe and/or |
27 | administer chemotherapy treatment shall: |
28 | (1) Provide written notice from the prescribing pharmacist to each patient undergoing such |
29 | treatment as to the hazards posed to patients and their families of extremely hazardous excretions, |
30 | including, but not limited to, urine, vomit, and feces, for a period following treatment as generally |
31 | determined by the food and drug administration label accompanying said chemotherapy drug or |
32 | drugs. To the extent such notices are generally consistent with those now provided for patients |
33 | undergoing treatment with radioactive drugs, or consistent with the recommendations of the World |
34 | Health Organization with regard to cytotoxic drugs, or otherwise consistent with similar standards |
| LC004806 - Page 3 of 19 |
1 | that may be approved by the department of environmental management in the context of a product |
2 | stewardship plan adopted pursuant to chapter 19.16 of title 23, then the prescribing pharmacist will |
3 | not be held liable for the form of such notice; |
4 | (2) Participate in an approved product stewardship program for the collection, safe and |
5 | proper disposal of extremely hazardous wastes, including cytotoxic drugs and related byproducts |
6 | and wastes adopted pursuant to chapter 19.16 of title 23 in order that providers and patients can |
7 | safely collect and contain extremely hazardous excretions for a period of time as determined by the |
8 | United States Food and Drug Administration ("FDA") and referenced on the relevant FDA |
9 | prescription insert(s). |
10 | (b) Cytotoxic drug producers shall provide for the costs of managing and safely disposing |
11 | of the health care waste identified in this section in accordance with chapter 19.16 of title 23. |
12 | (c) Receipt of notice from the party administering chemotherapy drugs or their agent |
13 | responsible for proper disposal of the hazardous wastes by the prescribing pharmacist or chief |
14 | pharmacist that the wastes have been disposed of in accordance with a product stewardship plan |
15 | shall satisfy the responsibility of the prescribing pharmacist hereunder. |
16 | (d) For the purposes of this section, extremely hazardous excretions shall mean any |
17 | excretion from a patient on a regimen of chemotherapy agents that are antineoplastic or cytotoxic, |
18 | and which may be excreted during the period of administration or the time period referenced in |
19 | subsection (c)(2) of this section, including, but not limited to, drugs listed in the NIOSH list of |
20 | antineoplastic and other hazardous drugs, as the same may be updated or amended from time to |
21 | time. |
22 | SECTION 3. Chapter 27-18.5 of the General Laws entitled "Nonprofit Hospital Service |
23 | Corporations" is hereby amended by adding thereto the following section: |
24 | 27-18.5-11. Cancer patient safety and environmental protection. |
25 | (a) Chemotherapy precautions following treatment. All physicians, pharmacists, or other |
26 | health care professionals licensed in the state of Rhode Island authorized to prescribe and/or |
27 | administer chemotherapy treatment shall: |
28 | (1) Provide written notice from the prescribing pharmacist to each patient undergoing such |
29 | treatment as to the hazards posed to patients and their families of extremely hazardous excretions, |
30 | including, but not limited to, urine, vomit, and feces, for a period following treatment as generally |
31 | determined by the food and drug administration label accompanying said chemotherapy drug or |
32 | drugs. To the extent such notices are generally consistent with those now provided for patients |
33 | undergoing treatment with radioactive drugs, or consistent with the recommendations of the World |
34 | Health Organization with regard to cytotoxic drugs, or otherwise consistent with similar standards |
| LC004806 - Page 4 of 19 |
1 | that may be approved by the department of environmental management in the context of a product |
2 | stewardship plan adopted pursuant to chapter 19.16 of title 23, then the prescribing pharmacist will |
3 | not be held liable for the form of such notice; |
4 | (2) Participate in an approved product stewardship program for the collection, safe and |
5 | proper disposal of extremely hazardous wastes, including cytotoxic drugs and related byproducts |
6 | and wastes adopted pursuant to chapter 19.16 of title 23 in order that providers and patients can |
7 | safely collect and contain extremely hazardous excretions for a period of time as determined by the |
8 | United States Food and Drug Administration ("FDA") and referenced on the relevant FDA |
9 | prescription insert(s). |
10 | (b) Cytotoxic drug producers shall provide for the costs of managing and safely disposing |
11 | of the health care waste identified in this section in accordance with chapter 19.16 of title 23. |
12 | (c) Receipt of notice from the party administering chemotherapy drugs or their agent |
13 | responsible for proper disposal of the hazardous wastes by the prescribing pharmacist or chief |
14 | pharmacist that the wastes have been disposed of in accordance with a product stewardship plan |
15 | shall satisfy the responsibility of the prescribing pharmacist hereunder. |
16 | (d) For the purposes of this section, extremely hazardous excretions shall mean any |
17 | excretion from a patient on a regimen of chemotherapy agents that are antineoplastic or cytotoxic, |
18 | and which may be excreted during the period of administration or the time period referenced in |
19 | subsection (c)(2) of this section, including, but not limited to, drugs listed in the NIOSH list of |
20 | antineoplastic and other hazardous drugs, as the same may be updated or amended from time to |
21 | time. |
22 | SECTION 4. Chapter 27-19 of the General Laws entitled "Nonprofit Medical Service |
23 | Corporations" is hereby amended by adding thereto the following section: |
24 | 27-19-77. Cancer patient safety and environmental protection. |
25 | (a) Chemotherapy precautions following treatment. All physicians, pharmacists, or other |
26 | health care professionals licensed in the state of Rhode Island authorized to prescribe and/or |
27 | administer chemotherapy treatment shall: |
28 | (1) Provide written notice from the prescribing pharmacist to each patient undergoing such |
29 | treatment as to the hazards posed to patients and their families of extremely hazardous excretions, |
30 | including, but not limited to, urine, vomit, and feces, for a period following treatment as generally |
31 | determined by the food and drug administration label accompanying said chemotherapy drug or |
32 | drugs. To the extent such notices are generally consistent with those now provided for patients |
33 | undergoing treatment with radioactive drugs, or consistent with the recommendations of the World |
34 | Health Organization with regard to cytotoxic drugs, or otherwise consistent with similar standards |
| LC004806 - Page 5 of 19 |
1 | that may be approved by the department of environmental management in the context of a product |
2 | stewardship plan adopted pursuant to chapter 19.16 of title 23, then the prescribing pharmacist will |
3 | not be held liable for the form of such notice; |
4 | (2) Participate in an approved product stewardship program for the collection, safe and |
5 | proper disposal of extremely hazardous wastes, including cytotoxic drugs and related byproducts |
6 | and wastes adopted pursuant to chapter 19.16 of title 23 in order that providers and patients can |
7 | safely collect and contain extremely hazardous excretions for a period of time as determined by the |
8 | United States Food and Drug Administration ("FDA") and referenced on the relevant FDA |
9 | prescription insert(s). |
10 | (b) Cytotoxic drug producers shall provide for the costs of managing and safely disposing |
11 | of the health care waste identified in this section in accordance with chapter 19.16 of title 23. |
12 | (c) Receipt of notice from the party administering chemotherapy drugs or their agent |
13 | responsible for proper disposal of the hazardous wastes by the prescribing pharmacist or chief |
14 | pharmacist that the wastes have been disposed of in accordance with a product stewardship plan |
15 | shall satisfy the responsibility of the prescribing pharmacist hereunder. |
16 | (d) For the purposes of this section, extremely hazardous excretions shall mean any |
17 | excretion from a patient on a regimen of chemotherapy agents that are antineoplastic or cytotoxic, |
18 | and which may be excreted during the period of administration or the time period referenced in |
19 | subsection (c)(2) of this section, including, but not limited to, drugs listed in the NIOSH list of |
20 | antineoplastic and other hazardous drugs, as the same may be updated or amended from time to |
21 | time. |
22 | SECTION 5. Chapter 27-20 of the General Laws entitled "Health Maintenance |
23 | Organizations" is hereby amended by adding thereto the following section: |
24 | 27-20-73. Cancer patient safety and environmental protection. |
25 | (a) Chemotherapy precautions following treatment. All physicians, pharmacists, or other |
26 | health care professionals licensed in the state of Rhode Island authorized to prescribe and/or |
27 | administer chemotherapy treatment shall: |
28 | (1) Provide written notice from the prescribing pharmacist to each patient undergoing such |
29 | treatment as to the hazards posed to patients and their families of extremely hazardous excretions, |
30 | including, but not limited to, urine, vomit, and feces, for a period following treatment as generally |
31 | determined by the food and drug administration label accompanying said chemotherapy drug or |
32 | drugs. To the extent such notices are generally consistent with those now provided for patients |
33 | undergoing treatment with radioactive drugs, or consistent with the recommendations of the World |
34 | Health Organization with regard to cytotoxic drugs, or otherwise consistent with similar standards |
| LC004806 - Page 6 of 19 |
1 | that may be approved by the department of environmental management in the context of a product |
2 | stewardship plan adopted pursuant to chapter 19.16 of title 23, then the prescribing pharmacist will |
3 | not be held liable for the form of such notice; |
4 | (2) Participate in an approved product stewardship program for the collection, safe and |
5 | proper disposal of extremely hazardous wastes, including cytotoxic drugs and related byproducts |
6 | and wastes adopted pursuant to chapter 19.16 of title 23 in order that providers and patients can |
7 | safely collect and contain extremely hazardous excretions for a period of time as determined by the |
8 | United States Food and Drug Administration ("FDA") and referenced on the relevant FDA |
9 | prescription insert(s). |
10 | (b) Cytotoxic drug producers shall provide for the costs of managing and safely disposing |
11 | of the health care waste identified in this section in accordance with chapter 19.16 of title 23. |
12 | (c) Receipt of notice from the party administering chemotherapy drugs or their agent |
13 | responsible for proper disposal of the hazardous wastes by the prescribing pharmacist or chief |
14 | pharmacist that the wastes have been disposed of in accordance with a product stewardship plan |
15 | shall satisfy the responsibility of the prescribing pharmacist hereunder. |
16 | (d) For the purposes of this section, extremely hazardous excretions shall mean any |
17 | excretion from a patient on a regimen of chemotherapy agents that are antineoplastic or cytotoxic, |
18 | and which may be excreted during the period of administration or the time period referenced in |
19 | subsection (c)(2) of this section, including, but not limited to, drugs listed in the NIOSH list of |
20 | antineoplastic and other hazardous drugs, as the same may be updated or amended from time to |
21 | time. |
22 | SECTION 6. Chapter 27-41 of the General Laws entitled "Health Maintenance |
23 | Organizations" is hereby amended by adding thereto the following section: |
24 | 27-41-90. Cancer patient safety and environmental protection. |
25 | (a) Chemotherapy precautions following treatment. All physicians, pharmacists, or other |
26 | health care professionals licensed in the state of Rhode Island authorized to prescribe and/or |
27 | administer chemotherapy treatment shall: |
28 | (1) Provide written notice from the prescribing pharmacist to each patient undergoing such |
29 | treatment as to the hazards posed to patients and their families of extremely hazardous excretions, |
30 | including, but not limited to, urine, vomit, and feces, for a period following treatment as generally |
31 | determined by the food and drug administration label accompanying said chemotherapy drug or |
32 | drugs. To the extent such notices are generally consistent with those now provided for patients |
33 | undergoing treatment with radioactive drugs, or consistent with the recommendations of the World |
34 | Health Organization with regard to cytotoxic drugs, or otherwise consistent with similar standards |
| LC004806 - Page 7 of 19 |
1 | that may be approved by the department of environmental management in the context of a product |
2 | stewardship plan adopted pursuant to chapter 19.16 of title 23, then the prescribing pharmacist will |
3 | not be held liable for the form of such notice; |
4 | (2) Participate in an approved product stewardship program for the collection, safe and |
5 | proper disposal of extremely hazardous wastes, including cytotoxic drugs and related byproducts |
6 | and wastes adopted pursuant to chapter 19.16 of title 23 in order that providers and patients can |
7 | safely collect and contain extremely hazardous excretions for a period of time as determined by the |
8 | United States Food and Drug Administration ("FDA") and referenced on the relevant FDA |
9 | prescription insert(s). |
10 | (b) Cytotoxic drug producers shall provide for the costs of managing and safely disposing |
11 | of the health care waste identified in this section in accordance with chapter 19.16 of title 23. |
12 | (c) Receipt of notice from the party administering chemotherapy drugs or their agent |
13 | responsible for proper disposal of the hazardous wastes by the prescribing pharmacist or chief |
14 | pharmacist that the wastes have been disposed of in accordance with a product stewardship plan |
15 | shall satisfy the responsibility of the prescribing pharmacist hereunder. |
16 | (d) For the purposes of this section, extremely hazardous excretions shall mean any |
17 | excretion from a patient on a regimen of chemotherapy agents that are antineoplastic or cytotoxic, |
18 | and which may be excreted during the period of administration or the time period referenced in |
19 | subsection (c)(2) of this section, including, but not limited to, drugs listed in the NIOSH list of |
20 | antineoplastic and other hazardous drugs, as the same may be updated or amended from time to |
21 | time. |
22 | SECTION 7. Title 23 of the General Laws entitled "HEALTH AND SAFETY" is hereby |
23 | amended by adding thereto the following chapter: |
24 | Declaration of findings. |
25 | (1) It is acknowledged by medical experts that bodily wastes of patients undergoing |
26 | chemotherapy treatment may contain levels of chemicals that are toxic, carcinogenic, mutagenic or |
27 | teratogenic for a certain period of time, to such an extent that The World Health Organization |
28 | defines genotoxic waste as chemotherapy drug waste including urine, feces and vomit from |
29 | patients, which may contain potentially hazardous amounts of the administered cytostatic drugs or |
30 | of their metabolites, and which should be considered genotoxic for at least forty-eight (48) hours |
31 | and sometimes up to one week after drug administration. According to the World Health |
32 | Organization ten percent (10 %) of known carcinogens are chemicals used to cure cancer. |
33 | (2) While, according to the American Society of Clinical Oncology, the cost of one |
34 | additional cancer patient resulting from the exposure to these harmful chemicals is approximately |
| LC004806 - Page 8 of 19 |
1 | one hundred seventy thousand dollars ($170,000) per treatment year, the cost of the implementation |
2 | of cytotoxic chemical safety protocols is estimated to be less than two percent (2%) of that cost. |
3 | (3) The World Health Organization further states that any discharge of genotoxic waste |
4 | into the environment could have disastrous ecological consequences. The World Health |
5 | Organization places the responsibility for genotoxic waste on the chief pharmacist and further states |
6 | that the chief pharmacist also has the special responsibility of ensuring that genotoxic products are |
7 | used safely, and that genotoxic waste is managed safely. |
8 | (4) The European Commission, Executive Agency for Health and Consumers undertook a |
9 | comprehensive "Study on the environmental risks of medicinal products" which was released in |
10 | June of 2014, drafted by BIO Intelligence Service, a division of Deloitte Consulting LLP, reviewing |
11 | the prevalence of contaminants in drinking water and noting the extreme dangers arising from |
12 | improper disposal of cytotoxic chemotherapy drugs. |
13 | (5) Dr. Christian G. Daughton, former chief of environmental chemistry for the United |
14 | States Environmental Protection Agency, notes in a paper entitled "Eco-directed sustainable |
15 | prescribing: feasibility for reducing water contamination by drugs" published in the journal |
16 | "Science of the Total Environment" on June 3, 2014, that generally, the best practice for lowering |
17 | the level of drugs in our environment is reduction of dosages, but that "[c]ertain drug classes |
18 | (especially cytotoxic chemotherapeutics) may not be amenable to this approach; the best control |
19 | measure for such highly toxic drugs may simply be the prevention of urine and feces from entering |
20 | sewers." |
21 | (6) The federal Occupational Safety and Health Administration ("OSHA") is the main |
22 | federal agency charged with the enforcement of safety and health legislation. OSHA, in concert |
23 | with the National Institute for Occupational Safety and Health ("NIOSH") and the Joint |
24 | Commission on Healthcare, an independent, not-for-profit organization that accredits and certifies |
25 | more than twenty thousand (20,000) health care organizations and programs in the United States, |
26 | stated in a 2011 letter to every hospital in the country that "[e]very day in healthcare settings across |
27 | America, workers are exposed to hundreds of powerful drugs used for cancer chemotherapy, |
28 | antiviral treatments, hormone regimens and other therapies. While these drugs are used to relieve |
29 | and heal patients, many of them present serious hazards to the health and safety of your workers. |
30 | Some of these drugs have been known to cause cancer, reproductive and developmental problems, |
31 | allergic reactions, and other adverse effects that can be irreversible even after low-level exposures." |
32 | (7) Further, because of the risk of ongoing exposure to these extremely hazardous excreted |
33 | drugs, the American Cancer Society has published a comprehensive list of safety precautions |
34 | regarding the in-home personal hygiene for individuals undergoing chemotherapy and their |
| LC004806 - Page 9 of 19 |
1 | families. |
2 | (8) Therefore, for the protection of both the public health and the environment, the general |
3 | assembly shall require that standards are set forth pursuant to this section to address this serious |
4 | health and safety issue. |
5 | CHAPTER 19.17 |
6 | SAFE CYTOTOXIC WASTE DISPOSAL ACT |
7 | 23-19.17-1. Short title. |
8 | This section shall be known and may be cited as the "Safe Cytotoxic Waste Disposal Act." |
9 | 23-19.17-2. Definitions. |
10 | As used in this chapter: |
11 | (1) "Cytotoxic drugs" means any drug defined by the department as extremely hazardous |
12 | waste or any waste byproduct or substance containing such a drug. |
13 | (2) "Department" means the Rhode Island department of environmental management. |
14 | (3) "Drug wholesaler'' means a business that sells or distributes cytotoxic drugs for resale |
15 | to an entity other than a consumer. |
16 | (4) "Entity" means a person other than an individual. |
17 | (5) "Mail-back program" means a system whereby residential generators of wastes from |
18 | cytotoxic drugs obtain prepaid and pre-addressed shipping containers in which to place wastes for |
19 | shipment to an entity that will dispose of them safely and legally. |
20 | (6) "Person" means an individual, firm, sole proprietorship, corporation, limited liability |
21 | corporation, general partnership, limited partnership, limited liability partnership, association, |
22 | cooperative, or other legal entity, however organized. |
23 | (7) "Plan" or "product stewardship plan" means a product stewardship plan required under |
24 | this chapter that describes the manner in which a product stewardship program will be provided. |
25 | (8) "Producer" shall be determined, with regard to a cytotoxic drug that is sold, offered for |
26 | sale, or distributed in Rhode Island as meaning one of the following: |
27 | (i) The person who manufactures a cytotoxic drug and who sells, offers for sale, or |
28 | distributes that cytotoxic drug in Rhode Island under that person's own name or brand. |
29 | (ii) If there is no person who sells, offers for sale, or distributes the cytotoxic drug in Rhode |
30 | Island under the person's own name or brand, the producer of the cytotoxic drug is the owner or |
31 | licensee of a trademark or brand under which the cytotoxic drug is sold or distributed in Rhode |
32 | Island, whether or not the trademark is registered. |
33 | (iii) If there is no person who is a producer of the cytotoxic drug pursuant to subsections |
34 | (8)(i) and (8)(ii) of this section, the producer of that cytotoxic drug is the person who brings the |
| LC004806 - Page 10 of 19 |
1 | cytotoxic drug into Rhode Island for sale or distribution. "Producer" does not include: |
2 | (A) A retailer that puts its store label on a cytotoxic drug; or |
3 | (B) A pharmacist who dispenses prescription drugs to, or compounds a prescribed |
4 | individual drug product for a consumer. |
5 | (9) "Product stewardship program" or "program" means a program financed and operated |
6 | by producers to collect, transport, and dispose of cytotoxic drugs. |
7 | (10) "Residential generators" means residential or other locations outside a hospital facility |
8 | where cytotoxic drugs are or may be excreted, unused, unwanted, disposed of, or abandoned. |
9 | (11) "Stewardship organization" means an organization designated by a producer or a |
10 | group of producers to act as an agent on behalf of each producer to operate a product stewardship |
11 | program. |
12 | 23-19.17-3. Product stewardship program. |
13 | (a) Requirement for sale. This chapter shall apply only to a producer whose cytotoxic drug |
14 | is sold or distributed in Rhode Island and shall be administered and implemented by the Rhode |
15 | Island department of environmental management. Each producer must: |
16 | (1) Operate, individually or jointly with other producers, a product stewardship program |
17 | approved by the department; or |
18 | (2) Enter into an agreement with a stewardship organization to operate, on the producer's |
19 | behalf, a product stewardship program approved by the department. |
20 | (b) Product stewardship program costs. |
21 | (1) A producer, group of producers, or stewardship organization must pay all |
22 | administrative and operational fees associated with their product stewardship program, including |
23 | the cost of collecting, transporting, and disposing of cytotoxic drugs collected from residential |
24 | generators and the proper disposal of packaging collected with the cytotoxic drugs. |
25 | (2) A producer, group of producers, or stewardship organization must pay for all fees |
26 | associated with their specific product stewardship program and product stewardship plan. |
27 | (3) No person or producer may charge a specific point-of-sale fee to consumers to recoup |
28 | the costs of their product stewardship program, nor may they charge a specific point-of-collection |
29 | fee at the time the unwanted products are collected from residential generators or delivered for |
30 | disposal. |
31 | (4) A producer, group of producers, or stewardship organization must pay all costs incurred |
32 | by the state of Rhode Island, including, but not limited to, the department in the administration and |
33 | enforcement of their product stewardship program. Exclusive of fines and penalties, the state shall |
34 | only recover its actual costs of administration and enforcement under this chapter and shall not |
| LC004806 - Page 11 of 19 |
1 | charge any amounts under this chapter in excess of its actual administrative and enforcement costs. |
2 | 23-19.17-4. Product stewardship plans. |
3 | (a) Plan content. Each product stewardship program shall have a product stewardship plan |
4 | that contains each of the following: |
5 | (1) Certification that the product stewardship program will accept all cytotoxic drugs |
6 | regardless of who produced them, unless excused from this requirement by the department as part |
7 | of the approval of the plan; |
8 | (2) Contact information for the individual and the entity submitting the plan and for each |
9 | of the producers participating in the product stewardship program; |
10 | (3) A description of the methods by which cytotoxic drugs from residential generators will |
11 | be collected in Rhode Island and an explanation of how the collection system will be convenient |
12 | and adequate to serve the needs of Rhode Island residents; |
13 | (4) A description of how the product stewardship plan will provide collection services for |
14 | cytotoxic drugs for all patients in Rhode Island that are convenient and adequate to meet the needs |
15 | of patients and caregivers, including the option for all patients to utilize a mail-back program; |
16 | (5) The timing and method of delivery to patients of shipping containers for a mail-back |
17 | program; |
18 | (6) A list containing the name, location, permit status, and record of any penalties, |
19 | violations, or regulatory orders received in the previous five (5) years by each person that will be |
20 | involved in transporting cytotoxic drugs and each disposal facility proposed to participate in the |
21 | product stewardship program; |
22 | (7) A description of how the cytotoxic drugs will be safely and securely tracked and |
23 | handled from collection through final disposal and the policies and procedures to be followed to |
24 | ensure security; |
25 | (8) A description of the public education and outreach activities to patients, caregivers, and |
26 | health care professionals, and how their effectiveness will be evaluated; |
27 | (9) A description of education and outreach efforts to law enforcement, public safety, |
28 | transportation officials and other personnel regarding the findings and requirements of this chapter, |
29 | and the process for safe handling and disposal of cytotoxic drugs and related wastes or byproducts |
30 | they may encounter; |
31 | (10) A description of how the scope and extent of the product stewardship program can |
32 | reasonably be expected to identify and address each instance in which a cytotoxic drug is prescribed |
33 | in Rhode Island; |
34 | (11) A starting date when collection of cytotoxic drugs will begin and, in the case of a |
| LC004806 - Page 12 of 19 |
1 | program utilizing a stewardship organization, the contracted term of engagement of that |
2 | stewardship organization; and |
3 | (12) If more than one producer will be involved in a proposed product stewardship |
4 | program, then the product stewardship plan for that program must include a fair and reasonable |
5 | manner for allocating the costs of the program among the participants in that program, in order that |
6 | the portion of costs paid by each producer is reasonably related to the amount of cytotoxic drugs |
7 | that producer sells in the state of Rhode Island. |
8 | (b) Department review, approval and updates: |
9 | (1) Nothing herein shall prevent an existing producer, group of producers, or stewardship |
10 | organization from collecting cytotoxic drugs and related waste and byproducts prior to the effective |
11 | date of this chapter. |
12 | (2) Product stewardship plans must be submitted to the department for approval. The initial |
13 | plans must be submitted by December 1, 2020. |
14 | (3) Within sixty (60) days after receipt of a product stewardship plan, the department shall |
15 | conduct a public hearing and determine whether the plan complies with the requirements of this |
16 | chapter and of any regulations adopted pursuant to this chapter. |
17 | (i) The department may reject a plan within thirty (30) days of receipt without conducting |
18 | a public hearing. |
19 | (ii) As part of its approval, the department may set reasonable performance goals for the |
20 | program. |
21 | (iii) If the department approves a plan, it shall notify the applicant of its approval in writing. |
22 | (iv) If the department rejects a plan, it shall notify the applicant in writing of its reasons for |
23 | rejecting the plan. |
24 | (4) An applicant whose plan has been rejected by the department must submit a revised |
25 | plan to the department within sixty (60) days after receiving notice of the rejection. |
26 | (5) If the department rejects a revised product stewardship plan or any other subsequently |
27 | revised plan, the producer(s) at issue shall be out of compliance with this chapter and are subject |
28 | to the enforcement provisions contained in this chapter. |
29 | (c) At least every three (3) years, a producer, group of producers or stewardship |
30 | organization operating a product stewardship program shall update its product stewardship plan |
31 | and submit the updated plan to the department for review and approval. |
32 | (d) A producer who begins to offer a cytotoxic drug for sale in the state of Rhode Island |
33 | after July 1, 2021, must submit a product stewardship plan to the department or provide evidence |
34 | of having joined an existing approved product stewardship program prior to the producer's initial |
| LC004806 - Page 13 of 19 |
1 | offer for sale of a cytotoxic drug. |
2 | (e) Any proposed changes to a product stewardship plan must be submitted in writing to |
3 | the department and approved by the department in writing prior to implementation of any change. |
4 | 23-19.17-5. Disposal of cytotoxic wastes. |
5 | (a) Compliance with applicable law. Each product stewardship program must comply with |
6 | all local, state, and federal laws and regulations applicable to its operations, including laws and |
7 | regulations governing the disposal of extremely hazardous wastes and their byproducts. |
8 | (b) Protocols for packaging and transport of cytotoxic drugs and related wastes from |
9 | residential generators must address the destruction of pathogens and cytotoxins and the conversion |
10 | of wastes to a non-liquid form prior to shipping or transport. |
11 | (c) Cytotoxic drugs and related wastes shall not be incinerated. |
12 | (d) Prior to shipment or transport from the location of the residential generator, the |
13 | cytotoxic drugs, related wastes (including, but not limited to, protective equipment, medical |
14 | supplies, clothing, bedding) and other contaminated materials must be contained to prevent |
15 | exposure by handlers of the waste during shipment or transport. |
16 | 23-19.17-6. Reporting. |
17 | (a) On or before July 1, 2021, (or at a later date as adopted in writing by the department) |
18 | and in each subsequent year, every producer, group of producers, or stewardship organization |
19 | operating a product stewardship program must prepare and submit to the department an annual |
20 | written report describing the program's activities during the previous reporting period. The report |
21 | must include the following: |
22 | (1) A list of producers participating in the product stewardship program; |
23 | (2) The quantity of cytotoxic drugs collected from residential generators; |
24 | (3) The name and location of disposal facilities at which cytotoxic drugs were disposed of |
25 | and the quantities disposed of at each facility; |
26 | (4) Whether policies and procedures for collecting, transporting, and disposing of cytotoxic |
27 | drugs, as established in the plan, were followed during the reporting period and a description of |
28 | any noncompliance; |
29 | (5) Whether any safety or security problems occurred during collection, transportation, or |
30 | disposal of cytotoxic drugs during the reporting period and, if so, what changes have or will be |
31 | made to policies, procedures, or tracking mechanisms to alleviate the problem and to improve |
32 | safety and security; |
33 | (6) A description of public education and outreach activities implemented during the |
34 | reporting period, including the methodology used to evaluate the outreach and program activities; |
| LC004806 - Page 14 of 19 |
1 | (7) How the product stewardship program complied with all other elements in the product |
2 | stewardship plan approved by the department, including its degree of success in meeting any |
3 | performance goals set by the department as part of its approval of the program; and |
4 | (8) Any other information that the department may reasonably require. |
5 | (b) For the purposes of this section, "reporting period" means the period beginning January |
6 | 1 and ending December 31 of the same calendar year. |
7 | (c) The department shall provide on its website a list of all producers participating in |
8 | product stewardship programs approved by the department and a list of all producers the |
9 | department has identified as noncompliant with this chapter or any regulations adopted pursuant to |
10 | this chapter. |
11 | 23-19.17-7. Rules, regulations and fees. |
12 | The director of the department of environmental management may, after a noticed public |
13 | hearing, promulgate rules and regulations as necessary to implement, administer, and enforce this |
14 | chapter. The rules and regulations shall include a schedule of fees to be charged to the producers |
15 | to cover all of the state of Rhode Island's costs of administering and enforcing this chapter. |
16 | 23-19.17-8. Enforcement by the department. |
17 | (a) The department of environmental management shall administer the penalty provisions |
18 | of this chapter. |
19 | (b) The department of environmental management may issue an administrative citation to |
20 | a producer for violation of this chapter or any rule or regulation adopted pursuant to this chapter. |
21 | The department shall first send a written warning to the producer as well as a copy of this chapter |
22 | and any rules and regulations adopted pursuant to this chapter. The producer shall have thirty (30) |
23 | days after receipt of the warning to comply and correct any violations. |
24 | (c) If the producer fails to comply and correct any violations, the department may impose |
25 | administrative fines for violations of this chapter or of any rules or regulations adopted pursuant to |
26 | this chapter. Each day shall constitute a separate violation for those purposes. |
27 | (d) Any person in violation of this chapter or any rule or regulation adopted pursuant to |
28 | this chapter shall be liable to the state of Rhode Island for a civil penalty in an amount not to exceed |
29 | one thousand dollars ($1,000) per day, per violation. Each day in which the violation continues |
30 | shall constitute a separate and distinct violation. |
31 | (e) In determining the appropriate penalties, the department of environmental management |
32 | shall consider the extent of harm caused by the violation, the nature and persistence of the violation, |
33 | the frequency of past violations, any action taken to mitigate the violation, and the financial burden |
34 | to the violator. |
| LC004806 - Page 15 of 19 |
1 | (f) Any producer receiving an administrative citation under this chapter or any rule or |
2 | regulation adopted pursuant to this chapter may file an appeal within twenty-one (21) calendar days |
3 | from the date the administrative citation was issued. The administrative citation is deemed issued |
4 | on the day it is sent by first class mail or personal service. The administrative citation shall state |
5 | the date of issuance. If the deadline falls on a weekend or state holiday, then the deadline shall be |
6 | extended until the next regular business day. The request to appeal must: |
7 | (1) Be in writing; |
8 | (2) Be accompanied by a deposit of the total fine and any fees noted on the administrative |
9 | citation; |
10 | (3) Specify the basis for the appeal in detail; |
11 | (4) Be postmarked within twenty-one (21) days from the date the administrative citation |
12 | was issued; and |
13 | (5) Be sent to the address as set forth on the administrative citation. |
14 | (g) The written request to appeal will be reviewed and, if found to be complete, a date, time |
15 | and place shall be set for a hearing before a hearing officer designated by the director of the |
16 | department of environmental management. Written notice of the time and place for the hearing will |
17 | be served by first class mail or personal service at least twenty one (21) days prior to the date of |
18 | the hearing to the producer appealing the citation. Service by first class mail, postage prepaid shall |
19 | be effective on the date of mailing. |
20 | (h) Failure of any producer to file an appeal in accordance with the provisions of this |
21 | section shall constitute waiver of that producer's rights to administrative determination of the merits |
22 | of the administrative citation and the amount of the fine and any fees and shall constitute a failure |
23 | by that producer to exhaust administrative remedies. |
24 | (i) The producer requesting the appeal may request the director of the department of |
25 | environmental management to recuse a hearing officer for reasons of actual prejudice against the |
26 | party's cause. The hearing officer shall conduct an orderly, fair hearing and accept evidence |
27 | pursuant to chapter 32 of title 45 (the "administrative procedures act") as follows: |
28 | (1) A valid administrative citation shall be prima facie evidence of the violation; |
29 | (2) Testimony shall be by declaration under penalty of perjury except to the extent the |
30 | hearing officer permits or requires live testimony concerning the violation. |
31 | (3) The hearing officer may reduce, waive or conditionally reduce the fines and any fees |
32 | stated in the administrative citation. The hearing officer may impose deadlines or a schedule for |
33 | payment of the fine and any fees due in excess of the deposit. |
34 | (4) The hearing officer shall make findings based on the record of the hearing and make a |
| LC004806 - Page 16 of 19 |
1 | written decision based on the findings entitled "hearing officer decision" (HOD). The HOD shall |
2 | be served by first class mail on the producer appealing and the department. The HOD affirming or |
3 | dismissing the administrative citation is final, unless a timely notice of appeal is filed for hearing |
4 | by the superior court. |
5 | 23-19.17-9. Appeal to superior court. |
6 | (a) An appeal may be filed with the superior court within ten (10) calendar days after the |
7 | date of service of the hearing officer decision. |
8 | (b) The appeal may be taken by any producer or the department within said ten (10) day |
9 | period, by filing with the clerk of the superior court a notice of appeal specifying the grounds for |
10 | the appeal. |
11 | (c) Upon receiving an appeal, the department shall immediately arrange for an |
12 | administrative record to be made available to the superior court of all of the documents constituting |
13 | the record upon which the hearing officer's decision was based. |
14 | (d) The superior court may hear additional evidence in its sole discretion and may sustain, |
15 | modify or overrule any order brought before it on appeal. |
16 | 23-19.17-10. Enforcement by attorney general. |
17 | (a) Upon the failure of any producer to comply with any requirement of this chapter and |
18 | any rule or regulation adopted pursuant to this chapter, the department of attorney general may |
19 | petition any court having jurisdiction for injunctive relief, payment of civil penalties and any other |
20 | appropriate remedy, including restraining such person from continuing any prohibited activity and |
21 | compelling compliance with lawful requirements; provided, however, this subsection does not |
22 | permit the department, the state of Rhode Island, or any court of competent jurisdiction to restrain |
23 | the sale of any cytotoxic drug in Rhode Island. |
24 | (b) Any person who knowingly and willfully violates the requirements of this chapter or |
25 | any rule or regulation adopted pursuant to this chapter is guilty of a misdemeanor and may be |
26 | prosecuted by the department of attorney general. A conviction for a misdemeanor violation shall |
27 | be punishable by a fine of not less than fifty dollars ($50.00) and not more than five hundred dollars |
28 | ($500) per day, per violation, or by imprisonment for a period not to exceed six (6) months or both. |
29 | 23-19.17-11. Construction and severability. |
30 | (a) Conflict with state or federal law. This chapter shall be construed in order to not conflict |
31 | with applicable federal or state laws, rules or regulations. |
32 | (b) Severability. If any of the provisions of this chapter or the application thereof to any |
33 | person or circumstance is held invalid, the remainder of those provisions, including the application |
34 | of any part or provisions to persons or circumstances other than those to whom it is held invalid |
| LC004806 - Page 17 of 19 |
1 | shall not be affected thereby and shall continue in full force and effect. |
2 | SECTION 8. This act shall take effect upon passage. |
======== | |
LC004806 | |
======== | |
| LC004806 - Page 18 of 19 |
EXPLANATION | |
BY THE LEGISLATIVE COUNCIL | |
OF | |
A N A C T | |
RELATING TO INSURANCE -- ACCIDENT AND SICKNESS INSURANCE POLICIES | |
*** | |
1 | This act would establish a program related to the disposal of extremely hazardous wastes |
2 | generated by the use of toxic, carcinogenic, mutagenic, or teratogenic chemotherapy drugs to be |
3 | implemented by pharmacists, physicians, health care providers, and insurers in this state. Further |
4 | this act would provide for a drug stewardship program to address procedures and industry financing |
5 | of the proper disposal of these extremely hazardous wastes. |
6 | This act would take effect upon passage. |
======== | |
LC004806 | |
======== | |
| LC004806 - Page 19 of 19 |